Literature DB >> 23563865

Structural and functional overview of the lectin complement pathway: its molecular basis and physiological implication.

Misao Matsushita1, Yuichi Endo, Teizo Fujita.   

Abstract

The complement system is an effector mechanism in immunity. It is activated in three ways, the classical, alternative and lectin pathways. The lectin pathway is initiated by the binding of mannose-binding lectin (MBL) or ficolins to carbohydrates on the surfaces of pathogens. In humans, MBL and three types of ficolins (L-ficolin, H-ficolin, and M-ficolin) are present in plasma. Of these lectins, at least, MBL, L-ficolin, and H-ficolin are complexed with three types of MBL-associated serine proteases (MASPs), MASP-1, MASP-2, and MASP-3 and their truncated proteins (MAp44 and sMAP). In the lectin pathway, the lectin-MASP complex (i.e., a complex of lectin, MASPs and their truncated proteins) binds to pathogens, resulting in the activation of C4 and C2 to generate a C3 convertase capable of activating C3. MASP-2 is involved in the activation of C4 and C2. MASP-1 activates C2 and MASP-2. The functions of MASP-3, sMAP, and MAp44 in the lectin pathway remain unknown. MASP-1 and MASP-3 also have a role in the alternative pathway. MBL and ficolins are able to bind to a variety of pathogens depending on their carbohydrate binding specificity, resulting in the activation of the lectin pathway. Deficiencies of the components of the lectin pathway are associated to susceptibility to infection, indicating an important role of the lectin pathway in innate immunity. The lectin-MASP complex is also involved in innate immunity by activating the coagulation system. Recent findings suggest a crucial role of MASP-3 in development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23563865     DOI: 10.1007/s00005-013-0229-y

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  17 in total

1.  Interaction of lectin pathway of complement-activating pattern recognition molecules with mycobacteria.

Authors:  M A Bartlomiejczyk; A S Swierzko; A Brzostek; J Dziadek; M Cedzynski
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

Review 2.  Compstatins: the dawn of clinical C3-targeted complement inhibition.

Authors:  Christina Lamers; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Trends Pharmacol Sci       Date:  2022-01-25       Impact factor: 17.638

3.  C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.

Authors:  Regina Tavano; Luca Gabrielli; Elisa Lubian; Chiara Fedeli; Silvia Visentin; Patrizia Polverino De Laureto; Giorgio Arrigoni; Alessandra Geffner-Smith; Fangfang Chen; Dmitri Simberg; Giulia Morgese; Edmondo M Benetti; Linping Wu; Seyed Moein Moghimi; Fabrizio Mancin; Emanuele Papini
Journal:  ACS Nano       Date:  2018-05-23       Impact factor: 15.881

Review 4.  Applying complement therapeutics to rare diseases.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Despina Yancopoulou; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Clin Immunol       Date:  2015-09-01       Impact factor: 3.969

Review 5.  Complement in disease: a defence system turning offensive.

Authors:  Daniel Ricklin; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2016-05-23       Impact factor: 28.314

Review 6.  Complement System Part I - Molecular Mechanisms of Activation and Regulation.

Authors:  Nicolas S Merle; Sarah Elizabeth Church; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

7.  A New Ligand-Based Method for Purifying Active Human Plasma-Derived Ficolin-3 Complexes Supports the Phenomenon of Crosstalk between Pattern-Recognition Molecules and Immunoglobulins.

Authors:  Aleksandra Man-Kupisinska; Mateusz Michalski; Anna Maciejewska; Anna S Swierzko; Maciej Cedzynski; Czeslaw Lugowski; Jolanta Lukasiewicz
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

8.  Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients.

Authors:  Julia Smedbråten; Geir Mjøen; Anders Hartmann; Anders Åsberg; Halvor Rollag; Tom Eirik Mollnes; Leiv Sandvik; Morten W Fagerland; Steffen Thiel; Solbjørg Sagedal
Journal:  BMC Nephrol       Date:  2016-10-18       Impact factor: 2.388

Review 9.  Mannan-binding lectin in cardiovascular disease.

Authors:  Izabela Pągowska-Klimek; Maciej Cedzyński
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

10.  Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours.

Authors:  Anna St Swierzko; Agnieszka Szala; Sambor Sawicki; Janusz Szemraj; Marcin Sniadecki; Anna Sokolowska; Andrzej Kaluzynski; Dariusz Wydra; Maciej Cedzynski
Journal:  Cancer Immunol Immunother       Date:  2014-07-20       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.